203 related articles for article (PubMed ID: 34058027)
1. Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study.
Baka-Ostrowska M; Bolong DT; Persu C; Tøndel C; Steup A; Lademacher C; Martin N
Neurourol Urodyn; 2021 Aug; 40(6):1490-1499. PubMed ID: 34058027
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.
Franco I; Hoebeke P; Baka-Ostrowska M; Bolong D; Davies LN; Dahler E; Snijder R; Stroosma O; Verheggen F; Newgreen D; Bosman B; Vande Walle J
J Pediatr Urol; 2020 Apr; 16(2):180.e1-180.e8. PubMed ID: 32007426
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
Rittig S; Baka-Ostrowska M; Tøndel C; Walle JV; Kjaeer B; Passier P; Bosman B; Stroosma O; Tannenbaum S
J Pediatr Urol; 2020 Feb; 16(1):31.e1-31.e10. PubMed ID: 31787582
[TBL] [Abstract][Full Text] [Related]
4. Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Kitta T; Darekar A; Malhotra B; Shahin MH; Jones P; Lindsay M; Mallen S; Nieto A; Crook TJ
J Pediatr Urol; 2023 Apr; 19(2):175.e1-175.e10. PubMed ID: 36504158
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction.
Sager C; Sanmartino M; Burek C; Gomez YR; Vazquez Patiño M; Weller S; Ruiz J; Lopez Imizcoz F; Tessi C; Szklarz T; Corbetta JP
J Pediatr Urol; 2020 Oct; 16(5):655.e1-655.e6. PubMed ID: 32800710
[TBL] [Abstract][Full Text] [Related]
6. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction.
Welk B; Hickling D; McKibbon M; Radomski S; Ethans K
Neurourol Urodyn; 2018 Nov; 37(8):2810-2817. PubMed ID: 30168626
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study.
Krhut J; Borovička V; Bílková K; Sýkora R; Míka D; Mokriš J; Zachoval R
Neurourol Urodyn; 2018 Sep; 37(7):2226-2233. PubMed ID: 29603781
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mirabegron for the treatment of low compliance bladder resulting from sacral/infrasacral lesions: A prospective study.
Vasudeva P; Yadav S; Madersbacher H; Kumar N; Prasad V; Saurav K; Kumar R; Borah D
Int J Urol; 2020 Jun; 27(6):552-558. PubMed ID: 32306426
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study.
Park JS; Lee YS; Lee CN; Kim SH; Kim SW; Han SW
World J Urol; 2019 Aug; 37(8):1665-1670. PubMed ID: 30511212
[TBL] [Abstract][Full Text] [Related]
10. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.
Amarenco G; Sutory M; Zachoval R; Agarwal M; Del Popolo G; Tretter R; Compion G; De Ridder D
Neurourol Urodyn; 2017 Feb; 36(2):414-421. PubMed ID: 26714009
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: A prospective study.
Vasudeva P; Prasad V; Yadav S; Kumar N; Saurav K; Prashanth YM; Tyagi V
Neurourol Urodyn; 2021 Feb; 40(2):666-671. PubMed ID: 33410559
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
Zachariou A; Filiponi M; Baltogiannis D; Giannakis J; Dimitriadis F; Tsounapi P; Takenaka A; Sofikitis N
Can J Urol; 2017 Dec; 24(6):9107-9113. PubMed ID: 29260636
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
18. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
19. Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder.
Kaga K; Yamanishi T; Kaga M; Fuse M; Kamasako T; Ishizuka M
Int J Urol; 2020 Oct; 27(10):899-904. PubMed ID: 32767525
[TBL] [Abstract][Full Text] [Related]
20. Long-term beneficial effects of mirabegron in pediatric patients with therapy-refractory neurogenic lower urinary tract dysfunction.
van Veen FEE; Schotman M; 't Hoen LA; Blok BFM; Scheepe JR
J Pediatr Urol; 2023 Dec; 19(6):753.e1-753.e8. PubMed ID: 37658014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
